Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy

Yavas G., Celik E., Yavas C., Elsurer C., Afsar R.

REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, vol.22, no.4, pp.295-302, 2017 (ESCI) identifier identifier identifier


Aim: We aimed to evaluate impact of spironolactone (S) on cardiovascular toxicity of concomitant use of radiotherapy (RT) and trastuzumab (T).